Xilio Therapeutics, Inc. Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc.

XLO

Rank in Stocks #17693
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to... Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
Share Price
$8.07
Last synced: 2026-11-13
Market Cap
$158.88M
Change (1 day)
-2.06%
Change (1 year)
-20.41%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for Xilio Therapeutics, Inc. (XLO)
EPS as of September 2026 TTM: $-0.25
According to Xilio Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.25. At the end of 2025 the company had an EPS of $-4.19, an increase over its 2024 EPS of $-15.26.
EPS history for Xilio Therapeutics, Inc. from 2019 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.25 -94.03%
2025 $-4.19 -72.54%
2024 $-15.26 -60.79%
2023 $-38.92 -13.66%
2022 $-45.08 -76.18%
2021 $-189.28 -87.18%
2020 $-1.48K 149.28%
2019 $-592.06 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 256.00%
US
$15.66 -6,364.00%
US
$-7.07 2,728.00%
US
$-5.29 2,016.00%
AU
$12.73 -5,192.88%
BE

Questions about Xilio Therapeutics, Inc.'s earnings per share (EPS)

What is Xilio Therapeutics, Inc.'s earnings per share (EPS)?

Xilio Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.25, as of Sep 2026.

What was Xilio Therapeutics, Inc.'s earnings per share (EPS) in 2025?

In 2025, Xilio Therapeutics, Inc.'s earnings per share (EPS) was $-4.19, compared with $-15.26 in 2024.

How has Xilio Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Xilio Therapeutics, Inc.'s earnings per share (EPS) was highest in 2025 ($-4.19) and lowest in 2020 ($-1.48K).

How does Xilio Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?

Xilio Therapeutics, Inc.'s earnings per share (EPS) ($-0.25) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.